COVID-19 is a multi-organ aggressor: epigenetic and clinical marks
The progression of coronavirus disease 2019 (COVID-19), resulting from a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, may be influenced by both genetic and environmental factors. Several viruses hijack the host genome machinery for their own advantage and survival, and sim...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Frontiers Media
2021
|
| _version_ | 1826296715447107584 |
|---|---|
| author | Kgatle, MM Lawal, I Mashabela, G Boshomane, T Koatale, P Mahasha, P Ndlovu, H Vorster, M Rodrigues, H Zeevaart, J Gordon, S Moura Alves, P Sathegke, M |
| author_facet | Kgatle, MM Lawal, I Mashabela, G Boshomane, T Koatale, P Mahasha, P Ndlovu, H Vorster, M Rodrigues, H Zeevaart, J Gordon, S Moura Alves, P Sathegke, M |
| author_sort | Kgatle, MM |
| collection | OXFORD |
| description | The progression of coronavirus disease 2019 (COVID-19), resulting from a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, may be influenced by both genetic and environmental factors. Several viruses hijack the host genome machinery for their own advantage and survival, and similar phenomena might occur upon SARS-CoV-2 infection. Severe cases of COVID-19 may be driven by metabolic and epigenetic driven mechanisms, including DNA methylation and histone/chromatin alterations. These epigenetic phenomena may respond to enhanced viral replication and mediate persistent long-term infection and clinical phenotypes associated with severe COVID-19 cases and fatalities. Understanding the epigenetic events involved, and their clinical significance, may provide novel insights valuable for the therapeutic control and management of the COVID-19 pandemic. This review highlights different epigenetic marks potentially associated with COVID-19 development, clinical manifestation, and progression.
|
| first_indexed | 2024-03-07T04:20:37Z |
| format | Journal article |
| id | oxford-uuid:cae39b1c-7169-4ea7-86fc-d9e8f73a64ed |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T04:20:37Z |
| publishDate | 2021 |
| publisher | Frontiers Media |
| record_format | dspace |
| spelling | oxford-uuid:cae39b1c-7169-4ea7-86fc-d9e8f73a64ed2022-03-27T07:10:49ZCOVID-19 is a multi-organ aggressor: epigenetic and clinical marksJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:cae39b1c-7169-4ea7-86fc-d9e8f73a64edEnglishSymplectic ElementsFrontiers Media2021Kgatle, MMLawal, IMashabela, GBoshomane, TKoatale, PMahasha, PNdlovu, HVorster, MRodrigues, HZeevaart, JGordon, SMoura Alves, PSathegke, MThe progression of coronavirus disease 2019 (COVID-19), resulting from a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, may be influenced by both genetic and environmental factors. Several viruses hijack the host genome machinery for their own advantage and survival, and similar phenomena might occur upon SARS-CoV-2 infection. Severe cases of COVID-19 may be driven by metabolic and epigenetic driven mechanisms, including DNA methylation and histone/chromatin alterations. These epigenetic phenomena may respond to enhanced viral replication and mediate persistent long-term infection and clinical phenotypes associated with severe COVID-19 cases and fatalities. Understanding the epigenetic events involved, and their clinical significance, may provide novel insights valuable for the therapeutic control and management of the COVID-19 pandemic. This review highlights different epigenetic marks potentially associated with COVID-19 development, clinical manifestation, and progression. |
| spellingShingle | Kgatle, MM Lawal, I Mashabela, G Boshomane, T Koatale, P Mahasha, P Ndlovu, H Vorster, M Rodrigues, H Zeevaart, J Gordon, S Moura Alves, P Sathegke, M COVID-19 is a multi-organ aggressor: epigenetic and clinical marks |
| title | COVID-19 is a multi-organ aggressor: epigenetic and clinical marks |
| title_full | COVID-19 is a multi-organ aggressor: epigenetic and clinical marks |
| title_fullStr | COVID-19 is a multi-organ aggressor: epigenetic and clinical marks |
| title_full_unstemmed | COVID-19 is a multi-organ aggressor: epigenetic and clinical marks |
| title_short | COVID-19 is a multi-organ aggressor: epigenetic and clinical marks |
| title_sort | covid 19 is a multi organ aggressor epigenetic and clinical marks |
| work_keys_str_mv | AT kgatlemm covid19isamultiorganaggressorepigeneticandclinicalmarks AT lawali covid19isamultiorganaggressorepigeneticandclinicalmarks AT mashabelag covid19isamultiorganaggressorepigeneticandclinicalmarks AT boshomanet covid19isamultiorganaggressorepigeneticandclinicalmarks AT koatalep covid19isamultiorganaggressorepigeneticandclinicalmarks AT mahashap covid19isamultiorganaggressorepigeneticandclinicalmarks AT ndlovuh covid19isamultiorganaggressorepigeneticandclinicalmarks AT vorsterm covid19isamultiorganaggressorepigeneticandclinicalmarks AT rodriguesh covid19isamultiorganaggressorepigeneticandclinicalmarks AT zeevaartj covid19isamultiorganaggressorepigeneticandclinicalmarks AT gordons covid19isamultiorganaggressorepigeneticandclinicalmarks AT mouraalvesp covid19isamultiorganaggressorepigeneticandclinicalmarks AT sathegkem covid19isamultiorganaggressorepigeneticandclinicalmarks |